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Abstract 
The recently released value assessment of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia by the Institute 
for Clinical and Economic Review (ICER) relies upon a long-term modeling exercise to support recommendations for what the ICER sees 
as the appropriate pricing for these products if prices are to be judged ‘cost-effective’. In this case, the recommendations are for a 
substantive price reduction of some 90% over WAC. Needless to say, this recommendation is unlikely to be welcomed with open arms 
by the respective manufacturers of valbenazine and deutetrabenazine. Unfortunately, as has been argued in a number of commentaries 
published over the past 18 months in INNOVATIONS in Pharmacy, the ICER endorsed health technology assessment methodology that 
underpins this exercise in building a modeled imaginary world to justify product pricing recommendations is fatally flawed: it does not 
meet the standards of normal science. Rather than addressing the issue of claims validation for VMAT2 products, the question of 
generating modeled evaluable claims, among others, for clinical, quality of life and resource utilization outcomes, the analysis focuses 
on claims that are neither  credible nor evaluable and, of course, non-replicable. A more positive and useful approach would be for ICER 
to focus on a framework where claims could be assessed in the short term to provide feedback to health system decision makers, 
physicians and patients. Instead, we are asked to believe that we can model 20 or 30 years into the future to establish non-evaluable 
claims for pricing and, ultimately, access. 
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Introduction 
Irrespective of the disease state that is under consideration, 
commentaries published in the past 18 months in 
INNOVATIONS in Pharmacy have pointed to the lack of 
scientific merit that can be accorded current standards in 
health technology assessment (HTA) 1. This is seen in the 
modeling of lifetime cost-per-quality adjusted life year (QALY) 
models to establish the notional cost-effectiveness of 
pharmaceutical products and devices.  These lifetime models 
or simulations of therapy interventions, where a target patient 
disease group with assumed characteristics is tracked by 
assumption  over  its remaining  assumed life expectancy, 
following an assumed staging of disease progression, are 
intended to generate a robust ‘value’ framework for 
‘informing’ health care decision makers. While the weight, if 
any, that decision makers place upon recommendations from 
constructing such imaginary worlds is unclear, the key point is 
that this is the methodology that ICER puts center stage in its 
value assessments. 
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Unfortunately, if this methodology is judged against the 
standards of normal science it fails. The modeled claims are 
not credible, evaluable or replicable. This has been pointed out 
in commentaries on ICER value assessments of heart failure 
(Entresto), multiple sclerosis, rheumatoid arthritis and 
cholesterol reduction (PCSK9 inhibitors)2 3 4 5. At the same 
time, a more recent commentary has stressed once again the 
limitations of the ICER methodology in a review of the recently 
updated value assessment framework6.  
 
Establishing a credible basis for pricing recommendations is of 
critical importance in marketing medications and devices. 
Unfortunately, modeled ICER recommendations are often 
taken at face value without health care decision makers 
necessarily understanding the mechanics and limitations of 
the modeling and value assessment methodology. This has the 
potential for limiting the commercial success of a product or 
device with possible adverse consequences for the target 
treatment population in limiting access to therapy. In the most 
recent commentary in INNOVATIONS in Pharmacy, attention 
was drawn to the refusal of ICER to allow access to the actual 
value assessment model7. While access to the model and 
independent assessments of the ICER model structure, 
including the options for developing alternative models that 
yield quite different recommendations, does not imply an 
acceptance of the lifetime cost-per-QALY methodology, access 
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does set the stage for challenging the model . A challenge 
which could make clear, as it is proposed to demonstrate here, 
that recommendations for pricing rest on an assumption 
driven construct given the lifetime or long-term perspective 
that is adopted. This does not mean, of course, that ICER 
should not continue to base value assessments on the 
construction of imaginary worlds. If ICER believes this makes a 
substantive and necessary input to formulary decisions then 
they should continue. Whether these models are of interest to 
health system decision makers is another question. 
 
Credible Claims  
The case to be put forward in this commentary is that the 
standards for cost-effectiveness and the subsequent 
recommendations for price adjustments in the ICER value 
assessment of vesicular monoamine transporter 2 (VMAT2) 
inhibitors in tardive dyskinesia are not , from the standpoint of 
normal science, acceptable. In presenting this case (and at the 
risk of going over ground that has been covered in previous 
commentaries in INNOVATIONS in Pharmacy), it needs to be 
reemphasized that if the standards of normal science are 
relevant in formulary decision making and pricing, then claims 
made for products should be in terms that are credible, 
evaluable and replicable. The standards of normal science, as 
they should apply in health technology assessment, are 
captured in the motto of the Royal Society (founded 1660; 
Royal Charter 1662): Nullius in verba (take no man’s word for 
it). If product claims, including those for cost-effectiveness, are 
to meet these standards then they have to: (i) involve the 
construction of an empirically evaluable, coherent model and 
(ii) facilitate the testing of hypotheses through 
experimentation or observation. A model is not to be judged 
by the realism of its assumptions  8 . To argue that a lifetime 
cost-per-QALY based claim is to be accepted as an input to 
formulary decision making on the grounds that the simulation 
is, by assumption, ‘realistic’ is unacceptable. Not only is it 
impossible to claim that a simulation projecting forward 20 or 
30 years is realistic but, as detailed below, health technology 
assessment standards in respect of pricing and compliance, 
ensure that it is not intended to be ‘realistic’. This, as noted in 
previous commentaries is succinctly put in the latest edition of 
the Canadian health care technology guidelines: Economic 
evaluations are designed to inform decisions. As such they are 
distinct from conventional research activities, which are 
designed to test hypotheses 9 10.  
 
The standards for hypothesis testing through experimentation 
and observation have been in place since the 17th century11. 
They demarcate science from pseudoscience or, as more 
strongly stated by Pigliucci, they demarcate natural selection 
from intelligent design12. Claims that meet the standards of 
normal science can apply to clinical outcomes, comparative 
effectiveness, quality of life, resource utilization, 
discontinuation in treatment practice and other measures 
relevant to formulary decisions. The point is that is possible to 
develop evaluable claims, to ensure feedback to decision 
makers where, for example, patients are tracked through  
observational studies to assess the impact of target therapies  
in treatment practice. 
 
ICER and VMAT2 Inhibitors 
Valbenazine (Ingreeza) and deutetrabenazine (Austedo) are 
two VMAT2 inhibitors approved by the Food and Drug 
Administration (FDA) in 2017; both indicated for tardive 
dyskinesia in adults.  Deutetrabenazine is also indicated for 
chorea associated with Huntington’s disease. ICER issued a 
draft evidence report for VMAT 2 inhibitors at the beginning of 
October 2017 and a response to comments from stakeholders 
together with the final evidence report on the 21st November 
2017 13   14 15.  The ICER value assessment also included 
tetrabenazine (Xenazine). As this product is used off-label in 
tardive dyskinesia and the data for it are limited, it is not 
included in this review. 
 
According to the ICER value assessment, the base-case 
modeled results for both products generated increased costs 
and increased QALYs compared to placebo over an assumed 
lifetime time horizon (Table ES9). The discounted lifetime 
costs, where no adjustment was made for possible price 
increases over the patent lifetime of the respective product, 
were $185,000 and $6,900 for valbenazine and its placebo 
comparator respectively, with corresponding discounted 
lifetime costs of $220,000 and $6,600 for deutetrabenazine. 
Lifetime modeled discounted QALYs were 15.35 for 
valbenazine and 15.37 for deutetrabenazine with their 
corresponding placebo discounted lifetime QALYs of 15.12 and 
15.18 respectively. The differences in these imaginary QALYs 
are 0.23 for valbenazine and 0.19 for deutetrabenazine 
(equivalent to a modeled projection of 84 days and 69 days 
respectively). The apparent precision that attaches to these 
QALY claims should not obscure the fact that they are entirely 
imaginary and, by construct, unevaluable. 
 
Expressed in discounted incremental cost effectiveness (ICER) 
terms in comparison with the placebo arm of the model g, 
lifetime ratios were $752,000 per QALY for valbenazine and 
$1.101 million per QALY for deutetrabenazine (Table ES10). As 
these are clearly outside a notional willingness-to-pay 
threshold of $150,00 per discounted QALY, the annual price 
required to achieve this for valbenazine (80 mg day) would 
have to be $11,260 (versus current annual WAC $75,789) and 
$9,158 (versus current annual WAC of $90,071) for 
deutetrabenazine ( 4 mg tablets/day).   
 
ICER also projected that costs per symptom-reduced year for 
tardive dyskinesia were approximately $71,000 for 
valbenazine and $105,000 for deutetrabenazine versus 
placebo. ICER notes:  It is difficult to judge the importance of 
these results, however, as there are no clear benchmarks of 
cost per tardive symptom-reduced year for comparison. These 
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may, however, be a   more relevant metric for health systems, 
particularly (as noted in previous commentaries) QALY 
measures are of little interest in US health care and are, under 
the Affordable Care Act (ACA) explicitly put to one side16. Once 
again, it is unclear how these imaginary claims would be 
evaluated, if indeed they were ever intended to be evaluated. 
 
Understandably, taken at face value, the results of this 
modeled outcome for price discounting to achieve a $150,000 
willingness-to-pay threshold will be of concern to the 
respective manufacturers. Against this modeled result, the 
case made in this commentary is, if the standards of normal 
science are applied, rather than accepting the construction of 
an imaginary world, these results should be put to one side. 
Any concern by manufacturers is misplaced.  
 
Irrespective of whether one believes or not that the standards 
of normal science apply in health technology assessment, the 
bottom line is that there is no universal ‘gold standard’ 
imaginary world in lifetime cost-per-QALY model building. All 
models rest upon decisions as to which model structures and 
assumptions appeal to the model builder. The inputs to the 
model rest on the vagaries of the available evidence, the 
assumptions driving how that evidence is manipulated and 
extrapolated, how those assumptions are ‘reasonably’ justified  
and the criteria proposed for determining whether the 
constructed incremental cost-per-QALY value meets notional 
willingness to pay thresholds. Pricing recommendations, for 
what they are worth, necessarily follow.  
 
Obviously, different models will yield different outcomes. 
Modifying assumptions within the model will yield different 
outcomes. In the absence of credible, evaluable and replicable 
claims to support hypothesis testing, one model is as ‘good’ (or 
as ‘bad’) as another. They all, however, share the same 
methodological flaw. Indeed, it would be a somewhat 
confusing situation if manufacturers and other stakeholders 
developed their own models. How would one model claim be 
judged from another? Would ICER claim the pole position? We 
could envisage a multiverse of models, each resting on 
modifications expressed as sensitivity scenarios from their 
own base-case lifetime scenarios. They all, however, share the 
same fatal methodological flaw.  A situation which, it has been 
noted in a previous commentary, is found in diabetes 
modeling17. 
 
Consider, as an example, evidence from a ‘revised’ ICER or 
competitor model that suggests a remodeled estimate of QALY 
gains. This is not an unreasonable outcome given the often 
dubious evidence base that supports utility assumptions in 
lifetime models.   If for example, the discounted lifetime QALY 
difference vs. placebo was 2.4 and not 0.24 for valbenazine, 
the ICER at $74,287 would be below the annual WAC. Would 
this lead to a recommendation for a WAC increase? Applying 
the same argument to the imaginary discounted QALY 
estimate for deutetrabenazine of 1.9 versus 0.19 would yield 
an ICER vs. placebo of $112,523. This would imply a 
significantly smaller price discount than recommended by 
ICER. 
 
While this example of varying estimated incremental QALYs is 
trivial, it points to the importance of challenging, within the 
model framework, key assumptions. In this case, the 
measurement of discounted QALY gains. Assuming one 
subscribes to the information role of creating imaginary worlds 
then a challenge could be made in the case of the VMAT2 
inhibitors. Unfortunately, in the model presented by ICER this 
is not the case. Comments received by ICER as part of the 
public comment process point to the absence of acceptable 
utility estimates. ICER in its response to the criticism that it 
understates the disutility of tardive dyskinesia argued that 
while there are ‘limited data on the impact of tardive 
dyskinesia on patient’s quality of life’ and that if data do 
emerge then ICER ‘may develop an evidence update on an ad 
hoc (emphasis added) basis’, the overriding consideration for 
ICER is to focus ‘its evaluations to inform policy decisions at or 
near the time of regulatory approval’.  A consideration which, 
presumably, has to be balanced against the evidence base and 
gaps in that evidence base. Or, put somewhat differently, the 
evidence for making the utility assumptions may be shaky, but 
we need to include it so that we can generate pricing 
recommendations in an ‘immediate’ timeframe.  
 
Whether ICER would ever return to a reassessment of utility 
scores or other assumptions is an open question. It would be 
hoped that ICER would both make a commitment and 
undertake to support studies that allowed them to revisit the 
utility scores. Unfortunately, as noted (see above) in a recent 
commentary in INNOVATIONS in Pharmacy, the refusal by ICER 
to give manufacturers and others access to the actual cost-
effectiveness model means that it is impossible to challenge 
the assumptions ICER deems appropriate 7. It is also impossible 
to judge the claim by ICER that the application of one-way 
sensitivity analyses and probabilistic sensitivity modeling 
overcome limitations in data inputs and even the absence of 
data in constructing imaginary worlds.   
 
While none of the manufacturers’ comments in respect of the 
VMAT2 inhibitors challenge the relevance of constructing a 
lifetime cost-per-QALY imaginary world, their comments and 
the ICER responses point to the flexibility accorded model 
builders in accepting or rejecting proposals to ‘modify’ 
assumptions.  The impression given in the responses by ICER is 
that while there are a number of unresolved issues and that 
these are unlikely to be resolved in the near future, to include 
QALY measures that may better align with patient and 
caregiver experience of tardive dyskinesia, ICER cannot wait 
until these data become available. ICER sees its mission as one 
of recognizing the paramount importance in informing 
decision makers of ICER’s assessment of the value of  products 
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in clinical practice; the model may be imperfect, assumptions 
have to be made and they ICER hopes to capture some 
uncertainty or the lack of evidence in their sensitivity analyses. 
This is the best of all possible imaginary worlds.   
 
The Clinical Evidence Base 
ICER admits that the evidence base for the clinical benefits and 
harms for valbenazine and deutetrabenazine is limited. In the 
case of  valbenazine three publications and five abstracts for 
the KINECT 2 and KINECT 3 placebo-controlled randomized 
clinical trials (RCTs) together with two open-label extensions 
supported the analysis, with two publications and seven 
abstracts  for two placebo controlled RCTs (ARM-TD and AIM-
TD) and one open-label extension supporting the 
deutetrabenazine model. The studies were rated good or fair 
quality. The limited number of studies together with protocol 
heterogeneity did not allow a formal indirect comparison of 
the two VMAT2 inhibitors.  
 
Trial duration was 6 weeks and 12 weeks for valbenazine and 
deutetrabenazine respectively. The primary endpoint in the 
valbenazine RCTs was the change in abnormal involuntary 
movement scale (AIMS) score at 6 weeks. Secondary outcomes 
were: investigator rated clinical global impression of change 
(CGIC) and patent reported clinical global impression of change 
(PCIC).  Both trials showed a significant improvement in AIMS 
scores (a 50% or more reduction) at six weeks while evidence 
for an improvement assessed by the CGIC was mixed with the 
KINECT 3 study showing no significant difference on the CGIC 
score and CGIC responders compared to placebo. Evidence 
was also mixed on improvements in PCIC with one trial 
reporting a statistically significant improvement but no 
difference in another. 
 
At 12 weeks, the primary efficacy endpoint was change from 
baseline in the AIMS score (> 50% improvement) for the 
deutetrabenazine trials. Both trials showed a statistically 
significant improvement over placebo. Evidence was mixed for 
the CGIC measure with differences observed in one of three 
arms of one trial and no difference observed in the other. 
There were no significant differences observed in the PGIC 
scale and in the modified craniocervical dystonia 
questionnaire (mCDQ-24). 
 
The limited number of trials and the mixed results, even with 
subsequent post-hoc, subgroup and pooled analyses of the 
data, point to the importance of basing assumptions for 
modeled efficacy and effectiveness claims on a comprehensive 
evidence base, to include replication of pivotal phase 3 trial 
results. While the results reported supported FDA 
recommendations, the limitations inherent in the trial designs, 
the duration of the trials and the reported primary (powered) 
and secondary (underpowered) endpoints point to the care 
that has to be taken in modeling. This is of particular import 
when these clinical outcomes are extrapolated for the lifetime 
of the respected modeled imaginary patient cohorts, even 
when therapy discontinuation assumptions are built into the 
model. 
 
Utilities and QALYs 
Given the role played by utilities in the VMAT2 inhibitor model 
and pricing recommendations based upon projected ICERs, it 
should be noted that none of the trials attempted to capture 
quality of life as a primary or even secondary endpoint. Apart 
from the obvious question of which quality of life instrument 
is appropriate in tardive dyskinesia (generic? condition 
specific?), the gains in utility scores, which are central to the 
ICER case for pricing adjustments were modeled from the 
literature. It is worth quoting in full the process by which the 
utility scores were derived. This is critical as the construction 
of the score is by assumption and not actually reported by 
patients experiencing moderate to severe tardive dyskinesia 
compared to controls. The value assessment states:  
The mean utility for the modeled population with 
improved TD was 0.82, which in part reflects utility 
scores associated with the underlying condition. 18 
19 To this utility, we applied utility decrement of 
0.095 to those patients with moderate to severe TD. 
The utility gained from improvement in TD was 
assumed to be independent of any other underlying 
conditions. We chose this utility decrement for TD 
because it was the only available utility estimate 
that directly assessed the impact of TD. The 
estimate was based on standard gamble utilities 
from subjects rating TD relative to perfect health 
and was directly elicited from healthy individuals 
upon viewing the symptoms of moderate to severe 
TD, independent of any underlying conditions. 
Limitations of soliciting utilities from healthy 
volunteers include that the final utility depends on 
the accuracy of the scenarios presented20. However, 
patients who have the condition in question often 
adapt to their conditions and frequently report 
utilities that are higher (or decrements that are 
smaller) than those reported from healthy 
volunteers. [Note: original references retained] 
 
Building assumption on assumption, with implicit assumptions 
regarding the application of standard gamble methodology 
drawn from a single study is questionable. In view of the 
importance of utility scores in the modeling, it might have 
been more appropriate for ICER to have undertaken their own 
empirical valuation of utility scores.   
 
The appropriateness of the standard gamble-based score was 
raised by Neurocrine Biosciences (valbenazine) in their public 
comment on the draft ICER model. They believed that the ‘TD 
disutility of 0.095 is too small to correctly capture the impact 
of TD’. They continue: ‘Our preliminary results show that the 
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mean EQ-5D index score (note: not clear if it is EQ-5D-3L or EQ-
5D-5L) for respondents with TD is 0.625 and the mean utility 
for propensity score matched respondents without TD is 0.750 
(a difference of 0.125)’. They suggest that a ‘utility decrement 
of at least double the value used is more appropriate‘.  
 
ICER, however, was not to be budged.  The response was that 
they had chosen the best available evidence for the impact of 
tardive dyskinesia on health utilities, giving the full benefits of 
completing eliminating tardive dyskinesia symptoms to all 
patients whose AIMS scores improved by 50% in clinical trials, 
together with sensitivity assessments. However, they do on to 
state that ‘As new evidence emerges, we may (emphasis 
added again) develop an evidence update on an ad hoc basis’. 
Given the short review timeframe, it is unlikely that the model 
outcomes reported in the ICER draft report could have been 
revisited. 
 
In a previous evaluation of an ICER value assessment, it was 
cautioned that a ‘rush to judgement’ might lead to modeled 
imaginary claims that might subsequently have to be 
‘modified’ (or even rejected). This caution, of course applies 
across the board to assumptions, including parameter 
distributions supporting sensitivity analyses. Utility has been 
singled out because of its central role but also, it is worth 
noting, because there are a range of quality of life instruments 
which yield, from underlying differences in their constructs, 
scoring algorithms and measurement properties, different 
scores for the same disease state and staging of severity in that 
disease state.  
 
Other Model Assumptions 
The authors of the cost-effectiveness model set out their key 
assumptions and the rationale for these in Table 5.3. Without 
going into the detail of this table it is worth noting how limited 
the evidence base actually was for model building, particularly 
where the focus was presumably on constructing a ‘believable’ 
lifetime cost-per-QALY imaginary world.  Consider four 
assumptions and their rationale: 
 
i. Response: The assumption was that therapy response 
remained constant for all responders; patients did not 
improve or decline beyond their initial response to 
therapy while remaining in the model ‘improved tardive 
dyskinesia‘ state. Rationale: There was limited 
information on the individual change in response to 
therapy over time; furthermore, there was no 
information available on the impact of tardive dystonia 
severity on quality of life. 
ii. Discontinuation: Long-term discontinuation rates were 
modeled from open-label studies with less than one 
year of observation. Following the first model cycle, 
discontinuation rates were modeled as being 50% of 
that observed in the first cycle. Rationale: There was no 
information regarding discontinuation rates of 
therapies beyond the clinical trial extensions. The 
discontinuation rate was lowered by 50% following the 
first year, it was argued, because for most therapies, 
patients typically discontinue their medications at a 
higher rate in the first year of treatment. 
iii. Resources: The assumption was that patients who 
responded to treatment were assumed to have no 
added primary care and  neurologist visit costs related 
to tardive dyskinesia; those not to treatment were 
assumed to have two additional primary care and two 
additional neurological visits per year. Rationale: There 
were no data on the costs associated with treating 
tardive dyskinesia; it was likely that patients whose 
tardive dyskinesia has improved will incur future office 
visits.  
iv. Mortality: The assumption was that tardive dyskinesia 
treatments have no effect on mortality. Rationale: no 
studies were identified demonstrating an impact of 
VMAT2 inhibitors on mortality in patients with tardive 
dyskinesia. 
From the perspective of the standards of normal science, in the 
absence of a modeling framework that is designed to generate 
credible, evaluable and replicable claims, a debate over the 
relative merits of competing assumptions seems pointless. 
Perhaps the only justification is that, as in the case of the two 
VMAT2 inhibitors, challenging ICER to justify assumptions for 
utility scores, quality of life claims, therapy adherence and 
persistence, will underscore the often tenuous empirical base 
on which the unevaluable modeled claims rest. Perhaps there 
should be standards for judging whether or not a model should 
be attempted if the information vacuum is ‘sufficiently empty’.   
 
Of course, we could only hope that when evidence gaps are 
noted in the construction of ‘believable’ imaginary worlds, the 
model builders or ICER could have suggested a research 
program to capture those data. These evidence gaps may be 
just as important to building credible and evaluable modeled 
claims as they are to future ‘ad hoc’ enhancements to the ICER 
model that have been promised in the response to public 
comments.  
 
Acknowledged Limitations 
Finally, it should be noted that, apart from the choice of 
assumptions to drive the model, the authors list what they 
consider to be limitations. The key limitations include (this list 
is not presumably exhaustive): 
 
• effectiveness data that were based on limited 
intermediate measures from clinical trials 
• current tardive dyskinesia severity measures that do 
not accurately reflect disease burden on overall 
quality of life 
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• a lack of data on discontinuation of tardive dyskinesia 
medication due to adverse events beyond the first 
year 
• lack of robust data on non-drug costs of tardive 
dyskinesia 
• inability to include sub-populations that may differ 
from the average tardive dyskinesia patient, due to a 
lack of sub-population data 
Acknowledging the limitations of the model must cast doubt 
on whether or not it is intended to be taken seriously. Or, more 
to the point, whether recommendations for imaginary ICERs 
and price reductions should be taken seriously. As it stands, 
the model presented in the ICER report is only one of many 
that could be constructed. Of course, if one wishes to maintain 
the integrity of constructing imaginary lifetime cost-per-QALY 
claims, then the prospect is that at some time, hopefully in the 
not too distant future, ICER will present a ‘revised’ model that 
recalibrates the ‘base-case’  to accommodate additional 
observations.  
 
Conclusion 
Previous commentaries on the ICER value assessment model 
have cautioned against taking recommendations for pricing 
adjustments at face value. For precisely the same arguments 
that have been put forward in this review of the VMAT2 
inhibitor models, previous recommendations have questioned 
the willingness to base recommendations on the construction 
of imaginary worlds. Further questions have to be raised when 
ICER then assess pricing decisions on the basis of budget 
constraints and the application of willingness-to-pay 
thresholds.  
 
The objections to this commitment to constructing imaginary 
worlds to support pricing adjustments are twofold: (i) there is 
any number of imaginary worlds that could be constructed and 
(ii) the creation of claims that are not credible, evaluable or 
replicable, failing to provide feedback to formulary 
committees, is unacceptable. Certainly, ICER can persevere in 
generating value assessments that rest upon imaginary 
constructs, defending data limitations through sensitivity 
analyses and the creation of targeted imaginary scenarios. 
Whether the construction of imaginary worlds can be said to 
‘inform’ decision makers is another question. The fundamental 
objection is that ICER value assessment models, however 
‘realistic’ the construct is intended to be, fail the standards of 
normal science. We have no idea if they are right or if they are 
wrong – and we will never know. 
 
What are possible next steps? This has been made clear in 
previous commentaries. Put to one side the obsession with 
creating imaginary worlds; the fact that these are a 
cornerstone of health technology assessment is irrelevant. The 
focus should be on the evidence base.  Can we develop 
evaluable short-term modeled claims, extrapolating from 
clinical trials, as opposed to claims stretching 20 or 30 years   
ahead? This would allow health systems to evaluate claims in 
treatment practice. If so, then we should put hasty and 
indefensible efforts at value assessment to one side, focusing 
instead on evaluating credible, evaluable and replicable claims 
for products such as valbenazine and deutetrabenazine.  
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